Artiva Biotherapeutics, Inc.ARTVEarnings & Financial Report
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf natural killer (NK) cell therapies for the treatment of cancers and autoimmune diseases. Its product pipeline covers both hematologic malignancies and solid tumors, and it operates primarily in the global biopharmaceutical sector, advancing accessible, high-efficacy immunotherapies to address unmet patient medical needs.
Revenue
$251.0K
Gross Profit
N/A
Operating Profit
$-16.2M
Net Profit
$-17.8M
Gross Margin
N/A
Operating Margin
-6450.2%
Net Margin
-7108.8%
YoY Growth
N/A
EPS
$-22.00
Financial Flow
Artiva Biotherapeutics, Inc. Q2 2024 Financial Summary
Artiva Biotherapeutics, Inc. reported revenue of $251.0K for Q2 2024, with a net profit of $-17.8M (-7108.8% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $251.0K |
|---|---|
| Net Profit | $-17.8M |
| Gross Margin | N/A |
| Operating Margin | -6450.2% |
| Report Period | Q2 2024 |
Artiva Biotherapeutics, Inc. Quarterly Revenue & Net Profit History
Artiva Biotherapeutics, Inc. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 2024 | $0 | — | $-17.5M | N/A |
| Q2 2024 | $251.0K | — | $-17.8M | -7108.8% |
Income Statement
| Q2 2024 | Q3 2024 | |
|---|---|---|
| Revenue | $251000 | $0 |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | |
|---|---|---|
| Assets | $75.9M | $225.6M |
| Liabilities | $50.6M | $24.6M |
| Equity | $-191.1M | $201.0M |
Cash Flow
| Q3 2024 | |
|---|---|
| Operating CF | $-11.6M |